<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01583816</url>
  </required_header>
  <id_info>
    <org_study_id>SP848-AK-1101</org_study_id>
    <nct_id>NCT01583816</nct_id>
  </id_info>
  <brief_title>Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions</brief_title>
  <official_title>Prospective, Randomized, Partly Blinded, in Part Placebo-controlled, Multicenter, Dose-finding Trial Exploring Safety, Tolerability and Efficacy of a Topical Resiquimod Gel in Patients With Multiple Actinic Keratosis Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spirig Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spirig Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Dose-Finding Study of Resiquimod Evaluating Safety and Efficacy in Patients with Multiple
      Actinic Keratosis Lesions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, partly blinded, in part placebo-controlled, multicenter dose-finding
      trial with patients suffering from AK. Patients were observed for efficacy, local
      tolerability and safety. A total of 14 sites in Switzerland and Germany enrolled male and
      female patients over 18 years of age with clinically diagnosed AK lesions Patients were
      randomized to receive resiquimod gel (Treatment Arms 1, 2, 3, 4, or 5) or matching vehicle
      (Treatment Arms 1-Pla, 2-Pla, or 3-Pla):

      Treatment Arms 1, 2 and 3: The patient was randomly assigned to one of three treatment groups
      and within each group there was one randomly assigned placebo patient for every two treatment
      patients (parallel-group randomization; 2:1 active vs placebo).

      Treatment Arms 4 and 5: The patient was randomly assigned to one of two treatment groups
      (parallel-group randomization, 1:1).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with complete clinical clearance in the treated area at the end of trial</measure>
    <time_frame>8 weeks after a maximal treatment period of 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of local tolerability (burning, itching, sensation of pain) by means of symptom scoring scales</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with partial clearance</measure>
    <time_frame>8 weeks after a maximal treatment period of 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of systemic tolerability [hematology, blood chemistry, vital signs]</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Resiquimod Gel 0.03% or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resiquimod gel 0.03% or placebo, once daily, 3x per week for 4 weeks, break of 8 weeks, repeated once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resiquimod or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, 7x within 2 weeks, break of 8 weeks, cycle repeated once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resiquimod or vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, 5x for 1 week, break of 8 weeks, cycle repeated once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resiquimod gel 0.01%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resiquimod gel 0.03%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resiquimod 0.03%</intervention_name>
    <description>topical application</description>
    <arm_group_label>Resiquimod Gel 0.03% or placebo</arm_group_label>
    <arm_group_label>Resiquimod or placebo</arm_group_label>
    <arm_group_label>Resiquimod or vehicle</arm_group_label>
    <arm_group_label>Resiquimod gel 0.03%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resiquimod 0.01%</intervention_name>
    <description>topical application</description>
    <arm_group_label>Resiquimod gel 0.01%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>topical application</description>
    <arm_group_label>Resiquimod Gel 0.03% or placebo</arm_group_label>
    <arm_group_label>Resiquimod or placebo</arm_group_label>
    <arm_group_label>Resiquimod or vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Male or nonpregnant, nonlactating female, ≥18 years

          -  A minimum of 2 clinically diagnosed AK-lesions within a defined area (25 cm2
             contiguous treatment area). One AK-lesion must have a diameter of at least 6 mm
             (indicator lesion)

          -  AK-lesions on balding scalp, forehead or face

        Exclusion Criteria:

          -  Known allergy or hypersensitivity to any of the trial gel ingredients

          -  Dermatological disease or condition that might be exacerbated by resiquimod gel
             treatment or may impair trial assessments

          -  Evidence of unstable or uncontrolled clinically significant medical conditions, active
             infection, immunosuppression or systemic cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars E French, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic of Dermatology, Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hauttumorcentrum Charité (HTCC)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Bonn - Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautzentrum</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLINIKUM VEST GmbH Knappschaftskrankenhaus</name>
      <address>
        <city>Recklinghausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>April 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2012</study_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>Resiquimod</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

